Physician profile
Parrish Sadeghi
NPI 1275567927
$3,424.52
in general payments reported to CMS, 2019-2025
29 companies · $533 in 2025
The $533 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $175 · 2021: $151 · 2022: $420 · 2023: $417 · 2024: $325 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $351.20 | 2019-2020 | |
| Pfizer INC. | $335.93 | 2019-2025 | |
| Allergan, INC. | $334.70 | 2019-2022 | |
| Leo Pharma INC. | $284.88 | 2019-2022 | |
| Abbvie INC. | $272.09 | 2023-2025 | Botox |
| Galderma Laboratories, L.P. | $245.41 | 2019-2025 | Aklief, Twyneo, Oracea |
| Janssen Biotech, INC. | $195.60 | 2022-2025 | Tremfya, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $184.79 | 2019-2024 | Winlevi |
| Almirall LLC | $152.28 | 2019-2024 | Seysara |
| Novo Nordisk INC | $122.41 | 2023 | |
| Merck Sharp & Dohme LLC | $114.70 | 2019 | |
| Revance Therapeutics, INC. | $104.13 | 2025 | Daxxify |
| Recordati_rare_diseases_inc. | $103.57 | 2025 | Isturisa |
| Mayne Pharma Commercial LLC | $99.86 | 2019 | |
| Genzyme Corporation | $94.21 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.01 | 2023 | Olumiant, Taltz |
| Epi Health, LLC | $56.01 | 2019 | |
| Organogenesis INC. | $53.60 | 2024-2025 | Nushield |
| Aclaris Therapeutics, INC. | $35.92 | 2019 | |
| Amgen INC. | $31.15 | 2023 | Otezla |
| Regeneron Healthcare Solutions, INC. | $28.26 | 2024 | Libtayo |
| Incyte Corporation | $27.91 | 2024 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $25.01 | 2025 | |
| Sanofi-Aventis U.S. LLC | $24.78 | 2019 | |
| Sandoz INC. | $24.50 | 2019 | |
| Verrica Pharmaceuticals INC. | $18.03 | 2025 | Ycanth |
| Promius Pharma LLC | $16.21 | 2019 | |
| Botanix Sb INC | $15.19 | 2025 | Sofdra |
| Smith+Nephew, INC. | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parrish Sadeghi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.